Literature DB >> 7051876

Extra-adrenal myelolipomas compared with extramedullary hematopoietic tumors: a case of presacral myelolipoma.

M R Fowler, R B Williams, J M Alba, C R Byrd.   

Abstract

A large presacral myelolipoma associated with increasing constipation is reported in a 70-year-old obese diabetic female. The resected tumor was encapsulated and dark red to yellow. Light and electron microscopy revealed mature and immature hematopoietic tissue, lymphoid aggregates and mature adipocytes. Myelolipomas arising in extra-adrenal sites are rare. Considered in the differential diagnosis are reactive extramedullary hematopoietic tumors that usually occur in patients with severe chronic anemias. Patients with extramedullary hematopoietic tumors are characterized by anemia, frequent hepatosplenomegaly and abnormal peripheral blood smears, and may be any age. The tumors are usually multiple and usually located in the mediastinum or epidural space. In contrast, patients with extra-adrenal myelolipomas are usually older than 40 years, have normal blood studies, absent hepatosplenomegaly, and usually have chronic debilitating diseases or endocrinopathies. Extra-adrenal myelolipomas are single and usually occur within the abdomen. Extramedullary hematopoietic tumors have a predominance of the hematopoietic component, with erythroid hyperplasia of that component. Extra-adrenal myelolipomas may have a predominance of either the hematopoietic or fatty component, chiefly the latter, and generally have a more conspicuous lymphocyte population. Although the components of these tumors are the same, we consider them separable clinically, pathogenetically and, in many cases, pathologically.

Entities:  

Mesh:

Year:  1982        PMID: 7051876     DOI: 10.1097/00000478-198206000-00009

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  27 in total

1.  Mediastinal extramedullary hematopoiesis as first manifestation of hereditary spherocytosis.

Authors:  A Pulsoni; G Ferrazza; F Malagnino; L Maurillo; E Pescarmona; A Picardi; E A Rendina; S Amadori
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

Review 2.  Myelolipoma of the lung: a case report and brief review.

Authors:  Katsuaki Sato; Yoshimichi Ueda; Shogo Katsuda; Katsuma Tsuchihara
Journal:  J Clin Pathol       Date:  2007-06       Impact factor: 3.411

3.  Urinary retention secondary to presacral myelolipoma; first reported case diagnosed by prostate TUR and requiring a cystectomy.

Authors:  A Orsola; C Raventós; I Trias; I Español; I Orsola
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

4.  Extramedullary hematopoiesis in unusual locations in hematologically compromised and noncompromised patients.

Authors:  Prabhakar Rajiah; Riku Hayashi; Thomas W Bauer; Murali Sundaram
Journal:  Skeletal Radiol       Date:  2011-02-23       Impact factor: 2.199

5.  Mediastinal extraadrenal myelolipoma: report of a case.

Authors:  Y Minamiya; S Abo; M Kitamura; K Izumi
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

Review 6.  Adrenal myelolipoma: a comprehensive review.

Authors:  Ábel Decmann; Pál Perge; Miklós Tóth; Peter Igaz
Journal:  Endocrine       Date:  2017-11-21       Impact factor: 3.633

7.  An Incidental Finding of Extra-adrenal Myelolipoma in the Upper Abdominal Cavity Attached to Mesentery: A Rare Case.

Authors:  Syed H Abbas; Geetika Goyal; Kate Yu; Abraham Loo
Journal:  Cureus       Date:  2019-06-04

8.  Focal hematopoietic hyperplasia of the rib--a form of pseudotumor.

Authors:  G Edelstein; M Kyriakos
Journal:  Skeletal Radiol       Date:  1984       Impact factor: 2.199

9.  Presacral myelolipoma: a case report and review of imaging findings.

Authors:  Kevin S Baker; Dwight Lee; Mingqian Huang; Elaine S Gould
Journal:  J Radiol Case Rep       Date:  2012-06-01

10.  An unusual case of multiple giant myelolipomas: clinical and pathogenetic implications.

Authors:  Kimberly H Allison; Gary N Mann; Thomas H Norwood; Brian P Rubin
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.